Physician profile
Yasmin Siddiqui
NPI 1194041665
$3,749.52
in general payments reported to CMS, 2019-2025
32 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 93% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $34.33 · 2021: $758 · 2022: $222 · 2023: $15.71 · 2024: $660 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,504.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $403.32 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.73 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $371.55 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $321.88 | 2021-2025 | Ozempic |
| Medtronic, INC. | $314.55 | 2024-2025 | Cobalt Dr Mri Surescan, Percepta Quad Crt-P Mri Surescan |
| Pfizer INC. | $221.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $188.21 | 2024-2025 | Wainua, Farxiga |
| Heartflow, INC. | $183.47 | 2025 | |
| Abbott Laboratories | $164.38 | 2021 | |
| Cvrx, INC. | $161.50 | 2024-2025 | Barostim Neo System |
| Amgen INC. | $155.17 | 2025 | Repatha, Evenity, Prolia |
| Corcept Therapeutics | $128.55 | 2025 | Korlym |
| Lantheus Medical Imaging, INC. | $83.00 | 2021-2024 | |
| Boston Scientific Corporation | $81.81 | 2023-2025 | General - Therapies, Watchman Flx |
| Exact Sciences Corporation | $72.74 | 2025 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $52.25 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.01 | 2025 | Caplyta |
| Saluda Medical Americas, INC. | $46.56 | 2025 | Evoke |
| Agepha Pharma Fz LLC | $46.02 | 2024-2025 | Lodoco |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.26 | 2022 | |
| Esperion Therapeutics, INC. | $35.77 | 2024-2025 | Nexletol |
| Baxter Healthcare | $33.07 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Lilly USA, LLC | $32.57 | 2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $30.90 | 2025 | Arexvy, Shingrix |
| Kiniksa Pharmaceuticals International, Plc | $24.67 | 2024 | Arcalyst |
| Phathom Pharmaceuticals, INC. | $23.50 | 2025 | Voquezna |
| Preventice Services, LLC | $22.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.94 | 2019 | |
| Vivus LLC | $18.10 | 2024 | Pancreaze |
| Inspire Medical Systems, INC. | $17.76 | 2025 | Inspire |
| Amarin Pharma, INC. | $17.67 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasmin Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.